<DOC>
	<DOC>NCT00866047</DOC>
	<brief_summary>This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.</brief_summary>
	<brief_title>A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with relapsed or refractory systemic ALCL who have previously received front line chemotherapy. Documented anaplastic lymphoma kinase (ALK) status. Histologicallyconfirmed CD30positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block. Fluorodeoxyglucoseavid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography. Received any previous autologous stem cell transplant at least 12 weeks (3 months) prior. At US sites, patients greater than or equal to 12 years of age may be enrolled. At nonUS sites, patients must be greater than or equal to 18 years of age. Previous treatment with brentuximab vedotin. Previously received an allogeneic transplant. Patients with current diagnosis of primary cutaneous ALCL (patients who have transformed to systemic ALCL are eligible). Known cerebral/meningeal disease.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Antigens, CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Lymphoma, Large-Cell, Anaplastic</keyword>
	<keyword>monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
</DOC>